- Report
- June 2020
- 163 Pages
Global
From €4008EUR$4,150USD£3,430GBP
- Report
- August 2019
- 110 Pages
Global
From €4781EUR$4,950USD£4,091GBP
- Report
- April 2019
- 15 Pages
Global
- Report
- January 2024
- 200 Pages
Japan
From €5553EUR$5,750USD£4,752GBP
- Report
- January 2024
- 100 Pages
Japan
From €1835EUR$1,900USD£1,570GBP
- Report
- November 2022
- 100 Pages
Global
From €2656EUR$2,750USD£2,273GBP
- Report
- January 2022
- 60 Pages
Global
From €1932EUR$2,000USD£1,653GBP
- Report
- January 2019
- 50 Pages
Global
From €1449EUR$1,500USD£1,240GBP
- Report
- January 2019
- 50 Pages
Global
From €1449EUR$1,500USD£1,240GBP
- Report
- December 2022
- 112 Pages
Global
From €4732EUR$4,900USD£4,050GBP
- Report
- August 2022
- 119 Pages
Global
From €4346EUR$4,500USD£3,719GBP
- Report
- June 2021
- 87 Pages
Global
€21248EUR$22,000USD£18,183GBP
- Drug Pipelines
- February 2019
- 300 Pages
Global
From €21248EUR$22,000USD£18,183GBP
- Report
- January 2019
- 14 Pages
United Kingdom
From €579EUR$599USD£495GBP
- Report
- August 2022
Global
From €1149EUR$1,190USD£984GBP
- Report
- August 2022
United States
From €1874EUR$1,940USD£1,603GBP
- Report
- August 2021
Global
From €3854EUR$3,990USD£3,298GBP
- Report
- August 2021
Europe
From €3303EUR$3,420USD£2,827GBP
- Report
- February 2021
Global
From €2859EUR$2,960USD£2,446GBP
- Report
- March 2023
- 1355 Pages
Global
From €2415EUR$2,500USD£2,066GBP
The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone.
The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more